Literature DB >> 26905810

Tacrolimus restores podocyte injury and stabilizes the expression of Cabin1 in 5/6 nephrectomized rats.

Yueqiang Wen1, Lingling Liu2, Peilan Zhou1, Huiyuan Li1, Zebin Wang1, Yajie Zhang1, Jianbo Liang1.   

Abstract

Podocyte injury is a vital factor, which induces massive proteinuria. Studies have shown that tacrolimus (TAC) protected podocyte via stabilizing cytoskeleton. Our latest study indicates that calcineurin binding protein 1 (Cabin1) undergoes nuclear translocation during podocytes injury. Whether TAC targets on Cabin1 during podocyte injury is still not clear. This study establishes non-immunological proteinuric model. To observe the effect of the treatment of TAC on Cabin1 expression in 5/6 nephrectomized rats. Sprague-Dawley rats were injected with TAC (0.2 mg/kg/day) for 4-8 weeks after 5/6 nephrectomy. Then, rats were sacrificed in the eighth week after operation, renal tissues were processed for morphological studies under light and electrical microscope. Cabin1 expression and distribution were detected by western blot and indirect immunofluorescence staining. In 5/6 nephrectomized rats, urinary protein excretion reached 90.2 ± 30.1 mg/24 h, glomerular sclerosis index and tubulointerstitial fibrosis score were significantly increased, and widespread of podocyte foot processes fusion was found. Moreover, Cabin1 protein expression was markedly increased, and its distribution became much more obviously in podocytes nuclei. In TAC treated rats, urinary protein excretion significantly decreased (44.9 ± 22.5 mg/24 h), glomerular sclerosis and tubulointerstitial fibrosis were alleviated, and podocyte foot processes fusion was inhibited. Furthermore, TAC alleviated the increased protein expression and abnormal distribution of Cabin1. In conclusion, TAC restores podocyte injury and stabilizes the expression of Cabin1. Cabin1 may become a new target to demonstrate the mechanism of TAC in podocyte injury.

Entities:  

Keywords:  Cabin1; Podocyte; Proteinuria; p53; tacrolimus

Mesh:

Substances:

Year:  2016        PMID: 26905810     DOI: 10.3109/0886022X.2016.1148936

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  6 in total

1.  Knocking down Cabin1 induces glomerular podocyte injury.

Authors:  Yueqiang Wen; Lingling Liu; Qingdong Xu; Peilan Zhou; Huiyuan Li; Zebin Wang; Jianbo Liang
Journal:  Int Urol Nephrol       Date:  2018-01-24       Impact factor: 2.370

2.  Population pharmacokinetics of tacrolimus in children with nephrotic syndrome.

Authors:  Guo-Xiang Hao; Xin Huang; Dong-Feng Zhang; Yi Zheng; Hai-Yan Shi; Yan Li; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2018-05-22       Impact factor: 4.335

3.  Effect of Vitamin D and Tacrolimus Combination Therapy on IgA Nephropathy.

Authors:  Dong Yuan; Zhan Fang; Fang Sun; Jing Chang; Jian Teng; Shuhua Lin; Xiaoming Liu
Journal:  Med Sci Monit       Date:  2017-06-29

4.  Atorvastatin protects against contrast-induced acute kidney injury via upregulation of endogenous hydrogen sulfide.

Authors:  Lin Yan; Lin Jiaqiong; Guo Yue; Li Xiaoyong; Tan Xuexian; Long Ming; Li Yinglan; Liao Xinxue; Huang Zena
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

5.  Tacrolimus alleviates LPS-induced AKI by inhibiting TLR4/MyD88/NF-κB signalling in mice.

Authors:  Xueqing Hu; Wenqian Zhou; Shun Wu; Rui Wang; Zhiyong Luan; Xin Geng; Na Xu; Zhaoyong Zhang; Zhenmin Ruan; Zenghui Wang; Furong Li; Chen Yu; Hongqi Ren
Journal:  J Cell Mol Med       Date:  2021-12-09       Impact factor: 5.310

6.  Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.

Authors:  Mi-Yeon Yu; Yong-Chul Kim; Ho Suk Koo; Ho Jun Chin
Journal:  PLoS One       Date:  2017-11-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.